Patents Assigned to Charterhouse Therapeutics Ltd.
  • Patent number: 7304186
    Abstract: A method of preparing prostanoid cross-conjugated dienones, via a tandem conjugate addition-Peterson olefination reaction route is described. Such compounds may be useful in medicine and other fields.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: December 4, 2007
    Assignee: Charterhouse Therapeutics Ltd.
    Inventors: Mazhar Iqbal, Paul Evans, Stanley Michael Roberts
  • Patent number: 7183440
    Abstract: A compound of formula (I) or (II): wherein A is hydrogen or CR1R2; Y and Z are each, independently, hydrogen or a halogen; X is —NR4R5, or R7; R1 is hydrogen, or a substituted or unsubstituted alkyl or alkenyl group containing 1–4 carbon atoms; when X is —NR4R5, R2 is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1–12 carbon atoms; when X is R7, R2 is an unsubstituted alkyl, alkenyl or alkynyl group, or a substituted or unsubstituted aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1–12 carbon atoms; R3 is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1–12 carbon atoms; R4 is hydrogen, a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl
    Type: Grant
    Filed: February 7, 2005
    Date of Patent: February 27, 2007
    Assignee: Charterhouse Therapeutics Ltd
    Inventors: Stanley Michael Roberts, Maria Gabriella Santoro, Vasudev Jadhav, Alan Michael Happe, Jérôme Dauvergne
  • Patent number: 7053119
    Abstract: The present invention provides methods and compositions for inhibiting IKK, as well as methods and compositions for identifying compounds with activity as inhibitors of IKK, and methods and compositions for the treatment of diseases and/or conditions wherein IKK is implicated and inhibition of its activity is desired. In addition, the present invention provides methods and compositions for the improving the therapeutic activity of COX2 inhibitors, comprising administering the COX2 to a subject in combination with a compound that inhibits IKK activity. The present invention further provides compositions that comprise compounds that inhibit IKK and COX2.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: May 30, 2006
    Assignees: The Regents of the University of California, Charterhouse Therapeutics Ltd.
    Inventors: Michael Karin, Pankaj Kapahi